Results 161 to 170 of about 7,827 (211)
The Antidepressant Effect and Safety of Non-Intranasal Esketamine: A Systematic Review [PDF]
BACKGROUND: The introduction of esketamine into the field of psychiatry comes on the heels of excitement from studies on racemic ketamine. While the intranasal route has been the most studied to date, other modes of administration of esketamine may also ...
Marije Aan Het Rot +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Asian Journal of Nursing Education and Research, 2023
Depression is more than feeling a little sad or "blue" for a few days. Antidepressant medications are used in the treatment of clinical depression, usually alongside other forms of therapy such as psychological or behavioral therapy. Spravato is a medicine used to treat adults with major depression that is resistant to treatment.
Nirosha V., Gayathri V.
openaire +1 more source
Depression is more than feeling a little sad or "blue" for a few days. Antidepressant medications are used in the treatment of clinical depression, usually alongside other forms of therapy such as psychological or behavioral therapy. Spravato is a medicine used to treat adults with major depression that is resistant to treatment.
Nirosha V., Gayathri V.
openaire +1 more source
Esketamine for treatment-resistant depression
Drug and Therapeutics Bulletin, 2020Generic name: Esketamine hydrochloride Brand name: Spravato Formulation: 28mg in 0.2ml nasal spray solution Market Authorisation holder: Janssen-Cilag International NV Indication: Treatment resistant
openaire +2 more sources
Esketamine for Treatment-Resistant Depression
JAMA PsychiatryTo the Editor Janik et al reported a positive trial of esketamine monotherapy for treatment-resistant depression. However, the lead-in design and functional unblinding could have biased treatment estimates. The 4-week double-blind phase was preceded by a lead-in phase of up to 7 weeks, during which time antidepressant medication was discontinued ...
Cristea, Ioana +2 more
openaire +4 more sources
NICE reconsiders esketamine for depression
BMJ, 2020The National Institute for Health and Care Excellence (NICE) has launched a second consultation on the use of esketamine for treatment resistant depression, after feedback showed that it could benefit some patients. Guidance published in January 2020 did not recommend esketamine for treatment resistant depression and said that the drug should not be ...
openaire +2 more sources
Esketamine for Postpartum Suicidality
Biological Psychiatry, 2021Catarina, Machado +3 more
openaire +2 more sources
Nervenheilkunde
ZUSAMMENFASSUNGKetamin blickt bereits auf eine längere Geschichte der Anwendung in der Psychiatrie zurück. Insbesondere ist es in den letzten 2 Dekaden zur Behandlung von therapieresistenten Depressionen erforscht und eingesetzt worden und ist mit dem Enantiomer Esketamin in Deutschland für diese Indikation zugelassen.
Cornelius Schüle +2 more
openaire +1 more source
ZUSAMMENFASSUNGKetamin blickt bereits auf eine längere Geschichte der Anwendung in der Psychiatrie zurück. Insbesondere ist es in den letzten 2 Dekaden zur Behandlung von therapieresistenten Depressionen erforscht und eingesetzt worden und ist mit dem Enantiomer Esketamin in Deutschland für diese Indikation zugelassen.
Cornelius Schüle +2 more
openaire +1 more source

